| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-12-23 |
| タイトル |
|
|
タイトル |
Association Between History of Rhythm Control Therapy and Clinical Outcomes in Atrial Fibrillation Patients With Stable Coronary Artery Disease: A Sub-Analysis of the AFIRE Trial |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
anti‐arrhythmia agents |
| キーワード |
|
|
言語 |
en |
|
キーワード |
atrial fibrillation |
| キーワード |
|
|
言語 |
en |
|
キーワード |
catheter ablation |
| キーワード |
|
|
言語 |
en |
|
キーワード |
coronary artery disease |
| キーワード |
|
|
言語 |
en |
|
キーワード |
treatment outcome |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
Wakatsuki, Daisuke
Suzuki, Hiroshi
海北, 幸一
WEKO
34072
e-Rad_Researcher
30346978
| ja |
海北, 幸一
宮崎大学
|
| ja-Kana |
カイキタ, コウイチ
|
| en |
Kaikita, Koichi
University of Miyazaki
|
Search repository
Akao, Masaharu
| en |
Akao, Masaharu（Personal）
National Hospital Organization Kyoto Medical Center
|
Search repository
Ako, Junya
Matoba, Tetsuya
Nakamura, Masato
Miyauchi, Katsumi
Hagiwara, Nobuhisa
Kimura, Kazuo
Hirayama, Atsushi
| en |
Hirayama, Atsushi（Personal）
Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital
|
Search repository
Matsui, Kunihiko
Ogawa, Hisao
Yasuda, Satoshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background
Rhythm control therapy improves the quality of life and prognosis of patients with atrial fibrillation (AF). We assessed the characteristics and clinical outcomes of AF patients with stable coronary artery disease (CAD) undergoing rhythm control therapy.
Methods
We analyzed 2215 participants from the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial, including 588 patients who received rhythm control therapy and 1627 who did not.
Results
At baseline, patients who received rhythm control therapy were generally younger, exhibited a higher prevalence of paroxysmal AF, experienced less heart failure, and had lower CHADS2 scores (CHF, hypertension, age ≥ 75 years, type 2 diabetes, and previous stroke or transient ischemic attack [doubled]) than those who did not. Among the rivaroxaban monotherapy and combination therapy groups, patients with a history of rhythm control therapy showed a lower incidence of the primary efficacy endpoint (a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death). However, following multivariate analysis and propensity score matching, no statistically significant difference in the primary efficacy endpoint was observed between patients with and without prior rhythm control therapy (adjusted HR 0.75, 95% CI 0.37–1.51, p = 0.43 in the rivaroxaban group; adjusted HR 0.75, 95% CI 0.43–1.30, p = 0.30 in the combination therapy group).
Conclusions
The initially observed benefit of rhythm control therapy was not significant after adjusting for baseline characteristics in patients with AF and stable CAD treated with rivaroxaban with or without additional antiplatelet therapy. |
|
言語 |
en |
| 書誌情報 |
en : Journal of arrhythmia
巻 41,
号 6,
p. e70210,
発行日 2025-11-19
|
| 出版者 |
|
|
出版者 |
Wiley |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
18804276 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/joa3.70210 |
| 権利 |
|
|
権利情報 |
© 2025 The Author(s). |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
Fulltext (1.1 MB)
.png)
